KSQ Comes Out Of Stealth Mode With $76m And Meeker As CEO

Emerging Company Profile: Former Sanofi-Genzyme exec David Meeker signed on to lead the startup, which is using a CRISPR-based drug discovery platform to develop specifically targeted therapies, with an initial focus on oncology and immunology, after leaving big pharma.

Emerging Company Profile Regular column feature image Version 2

KSQ Therapeutics hopes to reduce the time and costs associated with drug development with its proprietary platform for developing targeted therapies, and it has raised $76m and recruited former Sanofi-Genzyme executive David Meeker as its CEO to build a portfolio of drug candidates.

Cambridge, Mass.-based KSQ was founded by academics from four different institutions and two separate venture capital firms to create the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.